At Ashburton Eyecare, we are always fascinated by technologies that have the potential to improve patient care and protect vision. In a recent episode of The Stag Roar Podcast, we sat down with New Zealand ophthalmologist Dr Simon Dean to discuss one of the most exciting developments we have encountered in years: the Photon UVC device.

Corneal infections, known as microbial keratitis, remain one of the most urgent threats to vision worldwide. These infections can progress rapidly, leading to permanent scarring, vision loss, and in severe cases even blindness. Treatment often relies on intensive antibiotic therapy, but rising antimicrobial resistance and delayed access to treatment continue to present challenges.

The Photon device takes a remarkably different approach.

Rather than using chemicals or drugs, the device delivers a precise dose of 265nm UVC light directly to the surface of the eye. This specific wavelength targets the DNA of microorganisms, disrupting bacteria, fungi, and potentially viruses within seconds. According to Dr Dean, laboratory work has shown that a treatment lasting just a few seconds may achieve antimicrobial effects that previously required much longer treatment protocols.

What makes this particularly exciting is that the technology is already being used in veterinary medicine. Veterinary ophthalmologists around the world are evaluating the device as an additional tool alongside conventional treatments for eye infections in dogs and cats. Early reports suggest it may help reduce microbial load and support faster healing, while ongoing studies continue to build the evidence base.

For human eye care, the possibilities are significant.

Imagine a future where a patient presents with an early contact lens-related corneal infection and, alongside conventional treatment, receives a rapid light-based therapy designed to reduce the infectious burden immediately. Imagine reducing the risk of vision-threatening complications after eye surgery, or having another tool available when antibiotic resistance becomes a concern.

Importantly, Dr Dean emphasises that this technology is not intended to replace proven treatments today. Careful clinical trials are underway to establish both safety and effectiveness before any widespread use in human ophthalmology.

The journey from concept to clinic has taken more than 15 years of research, engineering, and perseverance. It is a reminder that some of the most exciting advances in eye care are happening at the intersection of optics, medicine, and technology.

To hear the full conversation with Dr Simon Dean and learn more about the Photon UVC device, watch our latest podcast episode on YouTube.